Elisa Agostinetto
Humanitas Clinical and Research Center, Milan

Optimal duration of immunotherapy: should I stay or should I go?
Disclosure of interest

- I have no actual or potential conflict of interest in relation to this presentation.
C.A., 59-year-old male

- **Medical history:** surgery for abdominal aortic aneurysm in 2011, total thyroidectomy for Basedow disease in 2005, haemorrhoidectomy in 2000

- **Ex-smoker** until 2012 (60 pack/year)

- **Comorbidities:** obesity (BMI 37.76), hypertension, hyperuricemia, iatrogenic hypothyroidism
26.03.2014 CT-guided lung biopsy: **lung adenocarcinoma** EGFR wt, ALK wt, cT3N3M1b (right adrenal gland)

16.04-25.06.2014 4 cycles of 1\textsuperscript{st} line chemotherapy with carboplatin AUC5 and pemetrexed 500 mg/mq, with lung progression disease (PD)

03.11-15.12.2014 3 cycles of 2\textsuperscript{nd} line chemotherapy with docetaxel 75 mg/mq with pericardial PD

26.12.2014 E.R. admission for cardiac tamponade:  
- pericardiocentesis with removal of 1500 ml (evidence of tumour cell at cytological examination);  
- echocardiogram: severe heart failure (EF 20-25%)  
- ECOG performance status (PS) 3

Progressive clinical improvement until ECOG PS 2
08.01-19.06.2015 3rd line therapy with erlotinib 150 mg, with initial partial response, followed by lung and adrenal PD

15.07-30.09.2015 4th line chemotherapy with gemcitabine 1250 mg/mq, with lung PD

30.11.2015-23.10.2017 5th line therapy with nivolumab (expanded access programme)
Baseline CT before Nivolumab

Baseline CT before Nivolumab

After 1 year of Nivolumab

After 1 year of Nivolumab

10.2017-09.2018 Complete remission of disease at follow-up
Conclusions

- 20 months of treatment with nivolumab with good tolerance to therapy resulted in complete remission of disease
- Persistence of complete remission of disease for 10 months after discontinuation of treatment

...still open question...

What is the optimal duration of immunotherapy?
CHECKMATE 153: RANDOMIZED RESULTS OF CONTINUOUS VS 1-YEAR FIXED-DURATION NIVOLUMAB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER


ESMO PRECEPTORSHIP PROGRAMME
Take Home messages

- The main benefit of IO agents is inducing very long-lasting responses
- Response may persist even after treatment discontinuation
- How to select patients who could stop IO after 2 years (only after CR)?
Thank you for your attention!